188 related articles for article (PubMed ID: 16596744)
41. From molecular diagnostics to personalized testing.
Finan JE; Zhao RY
Pharmacogenomics; 2007 Jan; 8(1):85-99. PubMed ID: 17187512
[TBL] [Abstract][Full Text] [Related]
42. Development of novel biomedicine based on genome science.
Baba Y
Eur J Pharm Sci; 2001 Apr; 13(1):3-4. PubMed ID: 11292562
[TBL] [Abstract][Full Text] [Related]
43. Integrating genomics technologies in health care: practice and policy challenges and opportunities.
Finley Austin MJ; Kreiner T
Physiol Genomics; 2002 Feb; 8(1):33-40. PubMed ID: 11842129
[TBL] [Abstract][Full Text] [Related]
44. Diagnosis or drug? Will pharmaceutical companies or diagnostics manufacturers earn more from personalized medicine?
Kling J
EMBO Rep; 2007 Oct; 8(10):903-6. PubMed ID: 17906670
[No Abstract] [Full Text] [Related]
45. Utilizing the molecular gateway: the path to personalized cancer management.
Overdevest JB; Theodorescu D; Lee JK
Clin Chem; 2009 Apr; 55(4):684-97. PubMed ID: 19246616
[TBL] [Abstract][Full Text] [Related]
46. Personalized medicine and development of targeted therapies: The upcoming challenge for diagnostic molecular pathology. A review.
Dietel M; Sers C
Virchows Arch; 2006 Jun; 448(6):744-55. PubMed ID: 16736190
[TBL] [Abstract][Full Text] [Related]
47. Pharmacogenetics approach to therapeutics.
Koo SH; Lee EJ
Clin Exp Pharmacol Physiol; 2006; 33(5-6):525-32. PubMed ID: 16700889
[TBL] [Abstract][Full Text] [Related]
48. Pharmacogenomics and the drug discovery pipeline: when should it be implemented?
Penny MA; McHale D
Am J Pharmacogenomics; 2005; 5(1):53-62. PubMed ID: 15727489
[TBL] [Abstract][Full Text] [Related]
49. SNPs--where's the beef?
Roses AD
Pharmacogenomics J; 2002; 2(5):277-83. PubMed ID: 12439733
[No Abstract] [Full Text] [Related]
50. A critical review of the Royal Society's report on personalized medicine.
Jain KK
Drug Discov Today; 2006 Jul; 11(13-14):573-5. PubMed ID: 16793525
[No Abstract] [Full Text] [Related]
51. The biomarker is not the end.
Nohaile M
Drug Discov Today; 2011 Oct; 16(19-20):878-83. PubMed ID: 21888986
[TBL] [Abstract][Full Text] [Related]
52. The impact of computing technology on pharmaceutical and biotech research.
Owen J
IDrugs; 2005 Oct; 8(10):834-7. PubMed ID: 16254804
[TBL] [Abstract][Full Text] [Related]
53. Personalized oncology: recent advances and future challenges.
Kalia M
Metabolism; 2013 Jan; 62 Suppl 1():S11-4. PubMed ID: 22999010
[TBL] [Abstract][Full Text] [Related]
54. Education: Teaching pharmacogenomics to prepare future physicians and researchers for personalized medicine.
Gurwitz D; Weizman A; Rehavi M
Trends Pharmacol Sci; 2003 Mar; 24(3):122-5. PubMed ID: 12628356
[TBL] [Abstract][Full Text] [Related]
55. From human genetics and genomics to pharmacogenetics and pharmacogenomics: past lessons, future directions.
Nebert DW; Zhang G; Vesell ES
Drug Metab Rev; 2008; 40(2):187-224. PubMed ID: 18464043
[TBL] [Abstract][Full Text] [Related]
56. Pharmacogenomics: the promise of personalized medicine for CNS disorders.
de Leon J
Neuropsychopharmacology; 2009 Jan; 34(1):159-72. PubMed ID: 18800072
[TBL] [Abstract][Full Text] [Related]
57. How personalized medicine is changing the rules of drug life exclusivity.
Sullivan CG
Pharmacogenomics; 2004 Jun; 5(4):429-32. PubMed ID: 15165178
[TBL] [Abstract][Full Text] [Related]
58. Integration of genomic technologies for accelerated cancer drug development.
Basik M; Mousses S; Trent J
Biotechniques; 2003 Sep; 35(3):580-2, 584, 586 passim. PubMed ID: 14513563
[TBL] [Abstract][Full Text] [Related]
59. Recent advances in biomarkers for cancer diagnosis and treatment.
Manne U; Srivastava RG; Srivastava S
Drug Discov Today; 2005 Jul; 10(14):965-76. PubMed ID: 16023055
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
